These results suggest that the activation of SIRT-1 by either modulating NAD+ availability or inhibiting other NAD+ consumers, such as PARP-1, could be an alternative means to activate SIRT-1 and perhaps to ameliorate, at least in part, the pathogenicity of sarcopenia. This evidence concerns the gene PARP1 and sarcopenia.